Symmetry Medical (NYSE: SMA) issued an update on its FY13 earnings guidance on Monday morning. The company provided EPS guidance of $0.40-0.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.63, Stock Ratings Network.com reports. The company issued revenue guidance of $400-415 million, compared to the consensus revenue estimate of $426.94 million.Symmetry Medical also updated its Q2 guidance to $0.06-0.08 EPS.
Symmetry Medical (NYSE: SMA) traded down 0.76% on Monday, hitting $9.17. Symmetry Medical has a 1-year low of $7.48 and a 1-year high of $12.83. The stock’s 50-day moving average is currently $10.. The company has a market cap of $341.8 million and a price-to-earnings ratio of 41.81.
Symmetry Medical (NYSE: SMA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.06 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.15 by $0.09. The company had revenue of $98.90 million for the quarter, compared to the consensus estimate of $106.04 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. The company’s quarterly revenue was down 1.8% on a year-over-year basis. Symmetry Medical has set its FY13 guidance at $0.64-0.76 EPS. Analysts expect that Symmetry Medical will post $0.63 EPS for the current fiscal year.
Symmetry Medical Inc. (NYSE: SMA) is an independent provider of implants and related instruments and cases to global orthopedic device manufacturers.
